IP Library Patent Application 17194093
Patent Application
App. No. 17/194,093

COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/194,093
Abstract

Compositions and methods for the treatment of viral infections include conjugates containing inhibitors of viral neuraminidase (e.g., zanamivir, peramivir, or analogs thereof) linked to an Fc monomer, an Fc domain, and Fc-binding peptide, an albumin protein, or albumin-binding peptide. In particular, conjugates can be used in the treatment of viral infections (e.g., influenza viral infections).

Claims (30)

1 . A conjugate described by formula (D-II-6):

wherein each E comprises an Fc domain monomer;

n is 1 or 2;

T is an integer from 1 to 20;

L is a linker;

R 7 is selected from C 1 -C 20 alkyl; and

the squiggly line indicates that L is covalently attached to E;

or a pharmaceutically acceptable salt thereof.

2 . The conjugate of claim 1 , wherein the squiggly line indicates that L is covalently attached to a nitrogen atom of a solvent-exposed lysine of E.

3 . The conjugate of claim 1 , wherein the squiggly line indicates that L is covalently attached to a sulfur atom of a solvent-exposed cysteine of E.

4 . The conjugate of claim 1 , wherein n is 2, and each E dimerizes to form an Fc domain.

5 . The conjugate of claim 1 , wherein T is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

6 . A population of conjugates of claim 1 , wherein the average value of T is 1 to 10, 5 to 10, 1 to 5, 3 to 7, or 3.5 to 5.5.

7 . The conjugate of claim 1 , wherein R 7 is methyl, ethyl, propyl, or butyl.

8 . The conjugate of claim 7 , wherein the conjugate is described by formula (D-II-7):

or a pharmaceutically acceptable salt thereof.

9 . The conjugate of claim 8 , wherein the conjugate is described by formula (D-II-8):

wherein L′ is the remainder of L, and

y 1 and y 2 are each independently an integer from 1-20,

or a pharmaceutically acceptable salt thereof.

10 . The conjugate of claim 9 , wherein the conjugate has the structure of:

or a pharmaceutically acceptable salt thereof.

11 . The conjugate of claim 10 , wherein the conjugate has the structure of:

or a pharmaceutically acceptable salt thereof.

12 . The conjugate of claim 11 , wherein n is 2, and each E dimerizes to form an Fc domain.

13 . The conjugate of claim 11 , wherein T is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

14 . A population of conjugates of claim 11 , wherein the average value of T is 1 to 10, 5 to 10, 1 to 5, 3 to 7, or 3.5 to 5.5.

15 . A method for the treatment of a subject having a viral infection, the method comprising administering to the subject an effective amount of a conjugate of claim 1 .

16 . A method for the prophylactic treatment of a viral infection in a subject in need thereof, the method comprising administering to the subject an effective amount of a conjugate of claim 1 .

17 . A method of preventing a secondary infection in a subject diagnosed with an influenza infection, the method comprising administering to the subject an effective amount of a conjugate of claim 1 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 23, 2021
From: BALKOVEC, JAMES M.; BENSEN, DANIEL C.; BORCHARDT, ALLEN; BRADY, THOMAS P.; CHEN, ZHI-YONG; COLE, JASON; DO, QUYEN-QUYEN THUY; DOEHRMANN, SIMON; JIANG, WANLONG; LAM, THANH; NONCOVICH, ALAIN; TARI, LESLIE W.
To: CIDARA THERAPEUTICS, INC.
Reel/Frame 057257/0830 →